Reference:
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., … & Madhi, S. A. (2021). Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. The New England Journal of Medicine, 384(20), 1899-1909. https://doi.org/10.1056/NEJMoa2103055
Summary:
The NVX-CoV2373 nanoparticle vaccine was evaluated in a phase 2 trial in South Africa during the B.1.351 variant’s prevalence. Among 2,684 seronegative participants, vaccine efficacy was 49.4%, with higher efficacy (60.1%) in HIV-negative individuals. Despite a notable safety profile, reactogenicity was more common in vaccine recipients. The trial indicates the vaccine’s potential against emerging variants, highlighting its efficacy in preventing symptomatic Covid-19.